FDA Eases Path for Restless Legs Nerve Stimulator
Published Date: 6/26/2026
Rule
Summary
The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Device moved to Class II — faster access
The FDA has classified the external lower extremity nerve stimulator for Restless Legs Syndrome as Class II (special controls). The order is effective June 26, 2026 (classification was applicable April 17, 2023), and FDA says this Class II classification will provide reasonable assurance of safety and enhance patients' access by reducing regulatory burdens.
De Novo ruling creates predicate for future devices
FDA states that when it classifies a device into Class I or II via the De Novo process, that device can serve as a predicate for future devices. As a result, other device sponsors can use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application.
New special controls set testing and labeling rules
FDA requires special controls for this device that include non-clinical performance testing (e.g., electrical stimulation parameters such as waveforms, maximum output voltage and current at 500 Ω, 2k Ω, and 10k Ω loads; pulse duration; frequency), electrode performance (adhesive integrity, shelf life, reusability), biocompatibility testing, electrical/thermal/mechanical safety and electromagnetic compatibility testing, software verification and validation, and physician and patient labeling (including recommended treatment regimens, typical sensations, methods to set stimulation intensity, electrode shelf life/reuse, and maintenance instructions).
Device is prescription-only
The external lower extremity nerve stimulator is identified as a prescription device and is for prescription use only. That means you must obtain a prescription from a health care provider to get this device.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12953 — Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Previous / Next Documents
Previous: 2026-12903 — Medical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval System
The FDA has officially placed the breast implant suction retrieval system into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make the device safer and easier to get to patients without unnecessary delays. The new classification took effect on June 26, 2026, and could speed up innovation while keeping costs in check for makers and users.
Next: 2026-12905 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep System
The FDA has officially placed the infant supine sleep system into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make sure the device is safe and effective while making it easier for companies to bring these helpful baby sleep products to market. The new classification took effect on June 26, 2026, but has been in place since March 30, 2023, so manufacturers and parents can breathe easy!